Is rituximab one for all ages and each sex?

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)602-603
Number of pages2
JournalBlood
Volume123
Issue number5
DOIs
StatePublished - Jan 30 2014

Fingerprint

Blood
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Is rituximab one for all ages and each sex? / Habermann, Thomas Matthew.

In: Blood, Vol. 123, No. 5, 30.01.2014, p. 602-603.

Research output: Contribution to journalArticle

@article{dc5531f89a874022af81b1626171f460,
title = "Is rituximab one for all ages and each sex?",
abstract = "In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit.",
author = "Habermann, {Thomas Matthew}",
year = "2014",
month = "1",
day = "30",
doi = "10.1182/blood-2013-12-543314",
language = "English (US)",
volume = "123",
pages = "602--603",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Is rituximab one for all ages and each sex?

AU - Habermann, Thomas Matthew

PY - 2014/1/30

Y1 - 2014/1/30

N2 - In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit.

AB - In this issue of Blood, Pfreundschuh et al report that young males treated with rituximab-based immunochemotherapy in contrast to elderly males benefit as much as females from rituximab immunochemotherapy and patients with more rapid rituximab clearance have reduced therapeutic benefit.

UR - http://www.scopus.com/inward/record.url?scp=84894079812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894079812&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-12-543314

DO - 10.1182/blood-2013-12-543314

M3 - Article

C2 - 24482494

AN - SCOPUS:84894079812

VL - 123

SP - 602

EP - 603

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -